Madrigal Pharmaceuticals
MDGL
MDGL
135 hedge funds and large institutions have $769M invested in Madrigal Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
39% less call options, than puts
Call options by funds: $19.2M | Put options by funds: $31.4M
Holders
135
Holding in Top 10
2
Calls
$19.2M
Puts
$31.4M
Top Buyers
| 1 | +$11.2M | |
| 2 | +$9.19M | |
| 3 | +$8.84M | |
| 4 |
Goldman Sachs
New York
|
+$8.3M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.21M |
Top Sellers
| 1 | -$64.8M | |
| 2 | -$8.01M | |
| 3 | -$4.48M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$4.16M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.37M |